According to industry sources on the 24th, companies including Yoo-Yu Pharmaceutical, Hanall Biopharma, HLB Therapeutics, RudaCure, and PNP Biopharm have entered the race to develop dry eye disease treatments.
Dry eye disease is known to have a very rigorous clinical process and approval criteria. Because it is a condition highly sensitive to environmental factors, it involves more variables than other clinical trials, and it is also difficult to objectively quantify drug efficacy based on patients' subjective responses.
Nevertheless, no domestic company has ever succeeded in developing a new drug for this condition, and with the global dry eye disease treatment market projected to expand to KRW 12 trillion by 2028, active research is underway.
Bioventure RudaCure is developing dry eye disease treatment candidate 'RCI001.' According to RudaCure, RCI001 is expected to demonstrate faster tear secretion efficacy and corneal damage recovery compared to commercially available competing drugs, along with superior instillation compliance and safety. The company anticipates that the drug will show rapid onset of action while significantly reducing side effects such as elevated intraocular pressure.